|
Market Cap (24-May) $66,720,148 (584th) |
Close (30-Jun) $0.040 |
Volume (30-Jun) 696,012 |
Shortsold (16-Jan) 98 (0.00%) (641st) |
|
52w High $0.099 |
52w Low $0.021 |
P/E 25.97 |
EPS 0 |
ACW released this announcement to the ASX on 1 March 2022, 8:58. The announcement is not marked as price sensitive, and is 18 page(s) in length and 2.21MB in size.
You can view all announcements from ACW and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACW was 0.064% short sold according to ASIC data. It was ranked the 508th most shorted stock on the ASX. It remains ranked 641st as of the latest reported data (16 January 2025).
| Other Recent Announcements from ACW | |
|---|---|
| ACW CEO presentation on emerging oral Alzheimers therapies | 21 June 2023, 8:50 |
| ACW CEO & CMO present at BIO International Convention | 5 June 2023, 9:06 |
| ACW AD trial amendment and Clinical Science Forum slides | 24 May 2023, 8:20 |
| ACW CEO Presents at European Life Sciences Conference | 1 March 2022, 8:58 |
| Appendix 4D & Half-Year Financial Statements | 24 February 2022, 12:50 |
| Actinogen appoints Prof Paul Rolan as Chief Medical Officer | 15 February 2022, 9:26 |
| Actinogen XanaMIA Part A trial results expected in April | 11 February 2022, 9:32 |
You must be logged in to post a reply.
Actinogen Medical 